From PICO anxiety to PICO strategy: planning for EU HTA success

Manufacturers

Get set for 2025: Mastering the new EU HTA statistical guidelines

Manufacturers

Value-Based Healthcare (VBHC): A game changer for pharma to accelerate patient access

Manufacturers

4 questions with Joanna Ng

Manufacturers

Unsupported policy information: Insights from Jane Ha

Manufacturers

Decoding payer perspectives: Insights from Ben Penley

Manufacturers

Leveraging Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Manufacturers

Forging ahead with US and EU healthcare policy changes: balancing sustainability, innovation and patient access in the era of IRA and EU HTA

Manufacturers

Emerging biopharma Outlook Therapeutics shares the benefits of Cencora's international commercialization support

Manufacturers

Value-Based Healthcare (VBHC): A game changer for pharma to accelerate patient access

Manufacturers

Q&A on the latest guidelines for statistical analysis in EU Health Technology Assessment

Manufacturers

4 questions with Ben Penley

Manufacturers

5 questions with Jane Ha

Manufacturers

6 questions with Kyle Noonan

Manufacturers

Recap AMCP 2024: Our thought leadership in action

Q&A Interview: Navigating the launch of ATMPs in Europe

Manufacturers

Benefit-driven pricing: How AMNOG strikes a balance between the financial burden on statutory health insurance and reimbursement of innovative medications in Germany

Manufacturers

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

Manufacturers

EAMS evidence: A key player in drug value proposition and NICE approval?

Manufacturers

HTAQ Summer 2024

Manufacturers

Market access brochure

Manufacturers

Anticipating issues, tackling challenges: Next steps with the JCA

Manufacturers

Are alternative access pathways the key to success for small pharma in European markets?

Manufacturers

Government Reliance on Value Assessments in Medicare Part B

Manufacturers

Webinar Insights: Navigating the changing landscape of Inflation Reduction Act (IRA) negotiations 

Manufacturers

Navigating new access hurdles in Europe: A conversation with Cencora’s EU HTA Lead

Manufacturers

Is NICE’s disease severity classification at risk?

Manufacturers

HTA Quarterly Spring 2024

Manufacturers

Rating the robots: Artificial intelligence for literature reviews

Manufacturers

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

Manufacturers

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

Manufacturers

Executive Insights: What's next with the Inflation Reduction Act (IRA)

Manufacturers

Planning for the World: Q&A With Sandra Anderson, SVP of International Commercialization at Cencora

Manufacturers

Addressing Barriers to Patient Care for People Living With Atopic Dermatitis

Shaping the future of healthcare: Our thought leadership at ISPOR Europe 2023

Manufacturers

Anticipating the top seven global market access trends for 2024: Cencora’s healthcare landscape outlook 

Manufacturers

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

Manufacturers

The Dutch Lock Procedure for Reimbursement: Ensuring Effective and Affordable Healthcare

Manufacturers

Enhancing Patient-Reported Outcomes (PROs) in German AMNOG Assessments: Insights from the ISPOR Europe 2023 Conference

Manufacturers

Will the IRA hinder the potential of Biosimilars?

Manufacturers

Patients at the center – Does the JCA truly embrace the patients’ voice?

Manufacturers

Exploring the Implications of Differing PICO Criteria for Oncology Drug Assessments in Europe

Manufacturers

Unlocking the Potential of Joint Clinical Assessment (JCA) in Europe: Insights from Industry Leaders and Experts

Manufacturers

Webinar on demand: Implications of the EU JCA on patient access and engagement

Manufacturers

Cost and resource burden of coverage with evidence development

Manufacturers

Does the EU HTAR really put patients at the center?

Manufacturers

HTA Quarterly Winter 2023

Manufacturers

Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared? 

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Manufacturers

Q&A – Preparing for the EU Joint Clinical Assessment (JCA) process

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

The cures conundrum: The importance of getting value assessment right for transformational therapies

Manufacturers

VPAS—Where next?

Manufacturers

Podcast: Collaborative perseverance to bring change to medicine access

Manufacturers

Multistakeholder perspectives on Joint Clinical Assessment in Europe

Panel explores insights and implications of the game-changing EU JCA

Manufacturers

Pharma Europe Q&A

Manufacturers

Empower your people and brand with biopharma learning solutions

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

Reimbursement considerations for home infusions

Manufacturers

How the JCA may help to address medicine inequality across Europe

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Answering four key questions about HTA market archetypes

Manufacturers

Six essential steps for emerging biopharma companies launching a new therapy

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Manufacturers

Innovation spotlight: Adding nursing support to at-home clinical trials